BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New 4Life Transfer Factor(R) Test Shows 73% Average Increase in Salivary IgA Production


5/8/2009 11:16:41 AM

SALT LAKE CITY, UT--(Marketwire - May 08, 2009) - 4Life Research™ announced today the completion of a new preliminary scientific test showing the effect of 4Life Transfer Factor Tri-Factor® Formula on IgA antibody production. Participants took 4Life Transfer Factor Tri-Factor Formula for two weeks, followed by 4Life Transfer Factor RioVida® Tri-Factor Formula for another two weeks. One hundred percent of participants saw an increase in the production rate of salivary secretory IgA when compared to a one-week baseline, with an average increase of 73%.

IgA antibodies, produced by plasma cells, are highly specific proteins used by the immune system to bind and neutralize foreign invaders. IgA bathes the surface of the mucous membranes. These y-shaped proteins bind to invaders, preventing them from attaching and passing through the mucous lining into the tissues and bloodstream of the body.

The test was conducted by 4Life Chief Executive Officer David Lisonbee; Chief Scientific Officer Calvin McCausland, Ph.D.; Health Sciences Advisory Board Member Richard Bennett, Ph.D.; Director of Health Information Services Brent Vaughan; and Research Scientist Shane Lefler.

"I'm proud to be associated with a company that values scientific research so highly," commented McCausland. "It's wonderful to provide effective immune system support products that are also backed up by sound scientific studies."

"I continue to be amazed at 4Life Transfer Factor's ability to boost and support the immune system," said Bennett. "This preliminary IgA test suggests another layer of vital immune system protection that 4Life Transfer Factor provides."

"4Life's Research and Development team has identified that 4Life Transfer Factor can support another vital component of a healthy immune system -- IgA antibodies -- once again proving our commitment to stay at the forefront of immune system science," remarked Lisonbee.

4Life, category creator of Transferceutical™ Science and world leader in the development, production, and distribution of Transfer Factor support products, continues to post growth in more than 40 countries around the world.


For more information:
www.4life.com
Calvin Jolley
Vice President, Strategic Development
4Life Research USA, LLC
801-560-7852
Email Contact



Read at BioSpace.com

4Life
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES